|Articles|June 26, 2011
Sulfonylurea monotherapy ups CVD risk vs. metformin in older diabetics
Older patients started on oral antidiabetic therapy with a sulfonylurea have significantly higher risk for cardiovascular disease (CVD) events than patients started on metformin.
Advertisement
Newsletter
Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Medical Economics
1
What medical practices need to know about the private equity resurgence
2
Improved physician leadership: A key to better health care
3
FDA clears neonatal MRI system designed for NICU use
4
Health care bankruptcies drop in 2025, but that doesn’t mean all is well for 2026
5


